These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1015 related items for PubMed ID: 10652037

  • 1. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
    Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH.
    Kidney Int; 2000 Feb; 57(2):601-6. PubMed ID: 10652037
    [Abstract] [Full Text] [Related]

  • 2. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.
    Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH.
    Kidney Int; 2003 May; 63(5):1874-80. PubMed ID: 12675866
    [Abstract] [Full Text] [Related]

  • 3. Add-on angiotensin receptor blockade with maximized ACE inhibition.
    Agarwal R.
    Kidney Int; 2001 Jun; 59(6):2282-9. PubMed ID: 11380832
    [Abstract] [Full Text] [Related]

  • 4. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy.
    Lacourcière Y, Bélanger A, Godin C, Hallé JP, Ross S, Wright N, Marion J.
    Kidney Int; 2000 Aug; 58(2):762-9. PubMed ID: 10916100
    [Abstract] [Full Text] [Related]

  • 5. Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Short-term observation.
    Tylicki L, Rutkowski P, Renke M, Rutkowski B.
    Am J Nephrol; 2002 Aug; 22(4):356-62. PubMed ID: 12169868
    [Abstract] [Full Text] [Related]

  • 6. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?
    Gansevoort RT, de Zeeuw D, de Jong PE.
    Kidney Int; 1994 Mar; 45(3):861-7. PubMed ID: 8196289
    [Abstract] [Full Text] [Related]

  • 7. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
    Krairittichai U, Chaisuvannarat V.
    J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
    de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM.
    Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice.
    Sasaki M, Uehara S, Ohta H, Taguchi K, Kemi M, Nishikibe M, Matsumoto H.
    Life Sci; 2004 Jul 02; 75(7):869-80. PubMed ID: 15183078
    [Abstract] [Full Text] [Related]

  • 12. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
    Jacobsen P, Andersen S, Jensen BR, Parving HH.
    J Am Soc Nephrol; 2003 Apr 02; 14(4):992-9. PubMed ID: 12660333
    [Abstract] [Full Text] [Related]

  • 13. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
    Schjoedt KJ, Jacobsen P, Rossing K, Boomsma F, Parving HH.
    Horm Metab Res; 2005 Apr 02; 37 Suppl 1():4-8. PubMed ID: 15918104
    [Abstract] [Full Text] [Related]

  • 14. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P, Rostaing L, Kamar N, Durand D.
    Presse Med; 2002 Nov 09; 31(36):1714-20. PubMed ID: 12467154
    [Abstract] [Full Text] [Related]

  • 15. Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?
    Andersen S, Tarnow L, Cambien F, Rossing P, Juhl TR, Deinum J, Parving HH.
    Kidney Int; 2002 Jul 09; 62(1):192-8. PubMed ID: 12081578
    [Abstract] [Full Text] [Related]

  • 16. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
    Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J, Diabetics Exposed to Telmisartan and Enalapril Study Group.
    N Engl J Med; 2004 Nov 04; 351(19):1952-61. PubMed ID: 15516696
    [Abstract] [Full Text] [Related]

  • 17. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.
    Rossing K, Christensen PK, Jensen BR, Parving HH.
    Diabetes Care; 2002 Jan 04; 25(1):95-100. PubMed ID: 11772908
    [Abstract] [Full Text] [Related]

  • 18. Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy.
    Jacobsen P, Rossing K, Rossing P, Tarnow L, Mallet C, Poirier O, Cambien F, Parving HH.
    Kidney Int; 1998 Apr 04; 53(4):1002-6. PubMed ID: 9551410
    [Abstract] [Full Text] [Related]

  • 19. Comparative effects of chronic ACE inhibition and AT1 receptor blocked losartan on cardiac hypertrophy and renal function in hypertensive patients.
    De Rosa ML, Cardace P, Rossi M, Baiano A, de Cristofaro A.
    J Hum Hypertens; 2002 Feb 04; 16(2):133-40. PubMed ID: 11850771
    [Abstract] [Full Text] [Related]

  • 20. Influence of angiotensin converting enzyme inhibition and angiotensin II type 1 receptor antagonism on renal sodium and water handling and albuminuria during infusion of atrial natriuretic factor into healthy volunteers.
    Vervoort G, Hertenberg F, Wetzels JF, Smits P.
    J Hypertens; 1998 Feb 04; 16(2):245-50. PubMed ID: 9535153
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.